Pharmacologic Advances in the Treatment and Prevention of Respiratory Syncytial Virus
Open Access
- 1 May 2010
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 50 (9), 1258-1267
- https://doi.org/10.1086/651603
Abstract
Currently, only 2 drugs have been approved for the treatment of respiratory syncytial virus (RSV). Palivizumab is a monoclonal antibody for the preveThis publication has 94 references indexed in Scilit:
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenThe New England Journal of Medicine, 2009
- The Secreted Form of Respiratory Syncytial Virus G Glycoprotein Helps the Virus Evade Antibody-Mediated Restriction of Replication by Acting as an Antigen Decoy and through Effects on Fc Receptor-Bearing LeukocytesJournal of Virology, 2008
- RSV 2007: Recent Advances in Respiratory Syncytial Virus ResearchViral Immunology, 2008
- Inhibition of Respiratory Syncytial Virus Infections With Morpholino Oligomers in Cell Cultures and in MiceMolecular Therapy, 2008
- Selection of a Respiratory Syncytial Virus Fusion Inhibitor Clinical Candidate. 2. Discovery of a Morpholinopropylaminobenzimidazole Derivative (TMC353121)Journal of Medicinal Chemistry, 2008
- Post-Infection A77-1726 Blocks Pathophysiologic Sequelae of Respiratory Syncytial Virus InfectionAmerican Journal of Respiratory Cell and Molecular Biology, 2007
- RSV604, a Novel Inhibitor of Respiratory Syncytial Virus ReplicationAntimicrobial Agents and Chemotherapy, 2007
- Function of the Respiratory Syncytial Virus Small Hydrophobic ProteinJournal of Virology, 2007
- The structural biology of type I viral membrane fusionNature Reviews Molecular Cell Biology, 2003
- RNA interferenceNature, 2002